• Shinichiro Uchiyama, Naoki Ishizuka, Kazuyuki Shimada, Tamio Teramoto, Tsutomu Yamazaki, Shinichi Oikawa, Masahiro Sugawara, Katsuyuki Ando, Mitsuru Murata, Kenji Yokoyama, Kazuo Minematsu, Masayasu Matsumoto, Yasuo Ikeda, and JPPP Study Group.
• From the Clinical Research Center for Medicine, International University of Health and Welfare, Tokyo, Japan (S.U.); Clinical Trial Department, Cancer Institute Hospital, Tokyo, Japan (N.I.); Department of Cardiology, Shin-Oyama City Hospital, Tochigi, Japan (K.S.); Teikyo Academic Research Center, Teikyo University, Tokyo, Japan (T.T.); Clinical Research Support Center, Center for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan (T.Y.); Diabetes and Life Style Disease Center, Fukujyuji Hospital, Tokyo, Japan (S.O.); Japan Physician's Association, Tokyo, Japan (M.S.); Department of Internal Medicine, Kitamura Memorial Clinic, Tokyo, Japan (K.A.); Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan (M. Murata); Department of Hematology/Oncology, Tokai University Hachioji Hospital, Tokyo, Japan (K.Y.); National Cerebral and Cardiovascular Center, Osaka, Japan (K.M.); Department of Clinical Neuroscience and Therapeutics, Hiroshima University, Hiroshima, Japan (M. Matsumoto); and Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan (Y.I.). suchiyama@iuhw.ac.jp.
• Stroke. 2016 Jun 1; 47 (6): 1605-11.

Background And PurposeThe effect of aspirin in primary prevention of stroke is controversial among clinical trials conducted in Western countries, and no data are available for Asian populations with a high risk of intracranial hemorrhage. The objective of this study was to evaluate the effect of aspirin on the risk of stroke and intracranial hemorrhage in the Japanese Primary Prevention Project (JPPP).MethodsA total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin. The median follow-up period was 5.02 years.ResultsThe cumulative rate of fatal or nonfatal stroke was similar for the aspirin (2.068%; 95% confidence interval [CI], 1.750-2.443) and no aspirin (2.299%; 95% CI, 1.963-2.692) groups at 5 years; the estimated hazard ratio was 0.927 (95% CI, 0.741-1.160; P=0.509). Aspirin nonsignificantly reduced the risk of ischemic stroke or transient ischemic attack (hazard ratio, 0.783; 95% CI, 0.606-1.012; P=0.061) and nonsignificantly increased the risk of intracranial hemorrhage (hazard ratio, 1.463; 95% CI; 0.956-2.237; P=0.078). A Cox regression adjusted by the risk factors for all stroke, which were age >70 years, smoking, and diabetes mellitus, supported the above result.ConclusionsAspirin did not show any net benefit for the primary prevention of stroke in elderly Japanese patients with risk factors for stroke, whereas age >70 years, smoking, and diabetes mellitus were risk factors for stroke regardless of aspirin treatment.Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00225849.© 2016 American Heart Association, Inc.

39 keywords...

hide…